- |||||||||| dexamethasone / Generic mfg., thalidomide / Generic mfg.
Clinical, P3 data, Journal, Combination therapy: Aponermin or placebo in combination with thalidomide and dexamethasone in the treatment of relapsed or refractory multiple myeloma (CPT-MM301): a randomised, double-blinded, placebo-controlled, phase 3 trial. (Pubmed Central) - Oct 15, 2023 Aponermin plus thalidomide and dexamethasone significantly improved PFS, OS and ORR with manageable side effects in RRMM patients who had received at least two prior therapies. These results support the use of aponermin, thalidomide, and dexamethasone as a treatment option for RRMM patients.
- |||||||||| dexamethasone / Generic mfg., bleomycin / Generic mfg.
Journal: Saikosaponin-d regulates angiogenesis in idiopathic pulmonary fibrosis through angiopoietin/Tie-2 pathway. (Pubmed Central) - Oct 15, 2023 DRd is associated with a significantly lower risk of disease progression or death compared to VRd as 1L treatment for TIE NDMM patients. This study has demonstrated that SSd could down-regulate the expression of ANG-1, Ang-2 and Tie2 in the Ang/Tie2 pathway, and may reduce lung inflammation and PF in BLM-induced mice via inhibition of angiogenesis.
- |||||||||| Breztri Aerosphere (budesonide/formoterol fumarate/glycopyrronium) / AstraZeneca
Long?term follow?up in patients treated with gene therapy for TDT beta?thalassemia and improved transduction towards a Phase IIb clinical trial () - Oct 15, 2023 - Abstract #ESGCT2023ESGCT_689; P=N/A In the collected hematopoietic tissues human cells showed VCN comparable to injected cells, indicating persisting marking in NSG?repopulating human progenitors. Overall, these results showed that addition of transduction enhancers to the culture protocol increases VCN/cell and TE in human repopulating cells, allowing to reduce the culture time preserving long term in vivo marking, and enabling the clinical development of a new Phase IIb trial.
- |||||||||| dexamethasone / Generic mfg.
Approaching optimal conditions for the treatment of Primary Hyperoxaluria Type 1 by in vivo lentiviral vector gene therapy () - Oct 15, 2023 - Abstract #ESGCT2023ESGCT_530; We observed a 29% reduction in urinary oxalate levels in LV?treated animals compared to untreated animals, achieving a partial reversion of the pathological phenotype.Overall, we observed a significant improvement of the proposed strategy in dexamethasone?treated adult PH1 mice and a 6?month maintenance of the therapeutic effect in three?week?old?treated mice. These results bring in vivo LV gene therapy a potential option for PH1 patients.
- |||||||||| hydrocortisone / Generic mfg.
Journal: Glucocorticoid Replacement for Adrenal Insufficiency and the Development of Non-Alcoholic Fatty Liver Disease. (Pubmed Central) - Oct 14, 2023 We could not find any significant correlations between single, daily or cumulative doses of glucocorticoids and the grade of liver steatosis, nor with fibrosis measured via validated sonographic techniques. In patients with adrenal insufficiency, glucocorticoid replacement within a physiological range of 15-25 mg hydrocortisone equivalent per day does not appear to pose an additional risk for the development of NAFLD, subsequent liver fibrosis, or the cardiovascular morbidity associated with these conditions.
- |||||||||| dexamethasone / Generic mfg.
Preclinical, Journal: Mfat-1 ameliorates cachexia after hypoxic-ischemic brain damage in mice by protecting the hypothalamus-pituitary-adrenal axis. (Pubmed Central) - Oct 14, 2023 In patients with adrenal insufficiency, glucocorticoid replacement within a physiological range of 15-25 mg hydrocortisone equivalent per day does not appear to pose an additional risk for the development of NAFLD, subsequent liver fibrosis, or the cardiovascular morbidity associated with these conditions. Our study provides mechanistic information for the development of intervention strategies to prevent cachexia.
- |||||||||| Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J, MetaBlok (lsalt peptide) / Arch Biopartners
Enrollment closed, Trial primary completion date: CATCO: Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial (clinicaltrials.gov) - Oct 13, 2023 P3, N=2900, Active, not recruiting, Dexamethasone has a good clinical effect on DKA patients complicated with AP. Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2023 --> Mar 2024
- |||||||||| remdesivir / Generic mfg., dexamethasone / Generic mfg.
Journal: Characterizing imbalance in the tails of the propensity score distribution. (Pubmed Central) - Oct 13, 2023 Visualization and variable importance techniques were helpful to identify variables most responsible for extreme propensity scores and may help identify individual characteristics that might make patients inappropriate for inclusion in the study (e.g., off-label use). Subsetting or restricting the study sample based on variables identified using this approach may help to avoid the need for trimming or overlap weights in studies.
- |||||||||| dexamethasone injection / Generic mfg.
Trial completion date, Trial primary completion date: POTEISS: Prediction of TEI Success in Sciatica (clinicaltrials.gov) - Oct 12, 2023 P=N/A, N=388, Recruiting, Trial primary completion date: Mar 2024 --> Sep 2023 Trial completion date: Dec 2023 --> Dec 2026 | Trial primary completion date: Dec 2023 --> Dec 2026
- |||||||||| dexamethasone / Generic mfg.
Preclinical, Journal: Impaired glucocorticoid receptor function attenuates herpes simplex virus 1 production during explant-induced reactivation from latency in female mice. (Pubmed Central) - Oct 12, 2023 The glucocorticoid receptor (GR) and the synthetic corticosteroid dexamethasone stimulate key viral transcriptional cis-regulatory modules, viral replication, and explant-induced reactivation from latency...Furthermore, female GR mice contained fewer VP16 + TG neurons compared to male GR mice or wild-type mice during the early stages of explant-induced reactivation from latency. Collectively, these studies revealed that GR transcriptional activity has female-specific effects, whereas male mice can compensate for the loss of GR transcriptional activation.
- |||||||||| dexamethasone / Generic mfg.
Preclinical, Journal: Effect of Ampelopsis brevipedunculata (Maxim.) Trautv extract on a model of atopic dermatitis in HaCaT cells and mice. (Pubmed Central) - Oct 12, 2023 The mice were applied DNCB and phosphate-buffered saline, dexamethasone (DX) or ABE-M (50, 100, and 200?mg/kg) was orally administrated for 28?days...Similarly, the expression of chemokines was suppressed by ABE-M in AD animal model induced by DNCB and the level of pro-inflammatory cytokines was decreased in a dose-dependent manner. Our research indicates that ABE-M could be a candidate material that can be used to improve skin immunity enhancement, health, and beauty.
- |||||||||| citarinostat (ACY-241) / BMS
Trial completion date, Trial primary completion date, Combination therapy: Study of ACY-241 Alone and in Combination With Pomalidomide and Dexamethasone in Multiple Myeloma (clinicaltrials.gov) - Oct 12, 2023 P1a/1b, N=85, Active, not recruiting, Our research indicates that ABE-M could be a candidate material that can be used to improve skin immunity enhancement, health, and beauty. Trial completion date: Jul 2023 --> Jan 2024 | Trial primary completion date: Jun 2023 --> Jan 2024
- |||||||||| Zilretta (triamcinolone acetonide ER) / Pacira
Trial completion date, Trial primary completion date: Use of Extended Release Triamcinolone in the Treatment of Rotator Cuff Disease (clinicaltrials.gov) - Oct 12, 2023 P3, N=65, Recruiting, Trial completion date: Jul 2023 --> Jan 2024 | Trial primary completion date: Jun 2023 --> Jan 2024 Trial completion date: Sep 2024 --> Dec 2024 | Trial primary completion date: Sep 2023 --> Dec 2023
- |||||||||| hydrocortisone / Generic mfg.
Journal: Successfully Managing Severe Anemia in a Trauma Patient Who Refused Blood Transfusion: A Case Report. (Pubmed Central) - Oct 12, 2023 Despite increased vasopressor dosage and addition of vasopressin and hydrocortisone, the patient became unresponsive with persistent hypotension...The patient responded well and subsequently recovered without blood transfusion. CONCLUSIONS This report has presented the clinical challenges of managing the case of a patient who requires but declines blood transfusion and has highlighted the approach to clinical care while respecting the wishes of the patient.
|